z-logo
Premium
Isotope labeled ‘HEA/HEE’ moiety in the synthesis of labeled HIV‐protease inhibitors—Part II
Author(s) -
Ekhato I. Victor,
Liao Yuan,
Plesescu Mihaela
Publication year - 2005
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.913
Subject(s) - indinavir , chemistry , amprenavir , saquinavir , moiety , protease , protease inhibitor (pharmacology) , darunavir , enzyme , stereochemistry , human immunodeficiency virus (hiv) , organic chemistry , hiv 1 protease , sida , virology , antiretroviral therapy , viral load , biology , viral disease
[ 2 H 5 ]‐Amprenavir and [ 2 H 5 ]‐saquinavir have been prepared from a common labeled precursor (1S, 2S)‐(1‐oxiranyl‐2‐[ 2 H 5 ]phenylethyl)‐carbamic acid tert‐ butyl ester, 1 . Both of these compounds are in the ‘HEA’ class of HIV protease inhibitors. [ 2 H 5 ]‐Indinavir, a representative of the ‘HEE’ group of protease inhibitors, has also been synthesized. In the case of indinavir, 1S‐(2,2‐dimethyl‐8, 8a‐dihydro‐3aH‐indeno‐[1,2‐d]‐oxazol‐3R‐yl)‐2‐oxiranylmethyl‐3‐[ 2 H 5 ]phenylpropan‐1‐one, 11 , provided the [phenyl‐ 2 H 5 ]‐HEE core structure for synthesis of the desired labeled compound. Copyright © 2005 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom